Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40% Kyverna began trading on the Nasdaq on Feb. 8, when it jumped 56% to reach a market cap of $1.4 billion.
Rep. Mast: It's important to have a true cognitive assessment of the commander in chief of the U.S. …